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INTRODUCTION
Govindan et al. reported on the incidence of small-lung cell carcinoma 
(SCLC) using the Surveillance, Epidemiology, and End Results (SEER) data-
base over the past three decades. They report that the incidence of SCLC 
as a percentage of the number of patients diagnosed with all types of lung 
cancer decreased from 17.26% in 1986 to 12.95% in 2002. The staging 
classification suggested by the Veterans Administration Lung Cancer Group 
(VALG) is widely used, and it divides patients into those with limited-stage 
disease and those with extensive-stage disease. At presentation, approxi-
mately 25% to 30% of patients will have local or regional disease, classified 
as limited-stage disease (1,2). 
In limited-stage SCLC with good performance status, chemotherapy plus 
thoracic radiotherapy achieved median survival in excess of 17 months 
and five-year survival rate of 12%–17% (3,4); in extensive stage disease, 
combination chemotherapy achieved median survival of 7 to 12 months and 
five-year survival rate of only 1%–2% (5). Despite high responsiveness to 
initial chemotherapy, >95% of patients with SCLC will die of this disease (3). 
The use of thoracic radiation has become standard in the combined modal-
ity treatment approach to limited-stage small-cell lung cancer. Traditionally, 
modest  total  doses  of  radiation,  ranging  from  45  to  50  Gy,  have  been 
employed because of the observed responsiveness of small cell lung cancer 
to radiotherapy. However, a review of the literature reveals high rates of 
local tumor relapse (6-9). 
Fried et al. (10) recently reported a meta-analysis regarding the timing of 
radiotherapy. Early radiotherapy was defined as beginning before 9 weeks 
since the initiation of chemotherapy and before the third cycle of chemo-
therapy. Late radiotherapy was defined as beginning 9 weeks or more after 
the initiation of chemotherapy or after the beginning of the third cycle of 
chemotherapy. Seven randomized trials with a total of 1,524 patients met 
the inclusion criteria. Six of the trials favored the use of early radiotherapy, 
and the overall risk ratio at 2 years was 1.17 (95% CI, 1.02-1.35; p=0.03). 
Current available data would support an improved survival when the tho-
racic radiation is delivered early in the course of treatment for patients with 
limited stage small cell lung cancer (10-13).
Historically, doses of 40 to 50 Gy delivered in 1.8 to 2.0 Gy daily fractions 
have been utilized in once-daily radiation schemes with data suggesting a 
dose response for doses between 30 and 50 Gy (14,15). Phase I trials have 
been performed suggesting the maximum tolerated dose for once-daily 
radiotherapy to be in the range of 70 Gy (15). Long-term survival data has 
been reported from the Cancer and Leukemia Group B. In a phase I trial of 
47 patients receiving dose-escalated thoracic radiation, the median survival 
was an encouraging 24 months (16). In a subsequent phase II experience 
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SUMMARY
Background: Small-cell lung cancer is highly chemo- and radiosensitive tumor. We evaluated two different radiotherapy 
doses applied sequentially with chemotherapy in relation to time to progression, progression free survival, and overall survival 
in patients with limited disease of small cell lung cancer. 
Methods: From 1998 to 2003, 81 patients were treated for small-cell lung carcinoma. Median age was 57 years (range, 
36-77 years) and female: male ratio was 1:4. Patients were initially treated with four cycles of chemotherapy during three 
weeks (cisplatin 80mg/m
2 IV, day 1 and etoposide 100 mg/m
2 IV, days 1 – 3). One month later, patients received up to 44 Gy, 
2 Gy per day, 5 days per week (group I, 41 patients) or above 44 Gy, standard fractionation (group II, 40 patients), to medi-
astinum and tumor. Range of higher radiotherapy doses was 54 Gy to 64 Gy, standard fractionation. We evaluated if different 
radiotherapy doses had any influence on time to progression, progression free survival, and overall survival.
Results: The median follow up time was 23 months (range, 12-72 months) for both groups of patients (81). The median time 
to progression in group I of patients (41) was 13 months (range, 11-29 months) while median time to progression in group II of 
patients (40) was 20 months (min=9, max=60). There was no statistically significant difference in relapse rate between two 
groups of patients (p>0.05, Fisher test). However, there was difference but not statistically significant in one-year progres-
sion free survival (p=0.05, chi square test) between groups, while there was statistically significant difference in two-year 
progression free survival favoring higher doses of radiotherapy (p<0.05, chi-square test). The median overall survival was 18 
months (range, 12-35 months) for group I of patients and 28 months (range, 15-72 months) for group II of patients. There 
was no statistically significant advantage between two groups of patients for one-year overall survival (p>0.05, chi-square 
test). However, there was statistically significant difference in overall survival favoring higher radiotherapy doses for two-year 
overall survival (p<0.05, chi-square test). 
Conclusion: We found that higher radiotherapy doses had an impact on long-term time to progression, progression free 
survival, and overall survival (2 years) of patients. 
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(Cancer and Leukemia Group B trial 39,808), (17) 57 patients were treated 
to 70 Gy in 35 fractions concurrent with carboplatin and etoposide after two 
prior cycles of paclitaxel and topotecan. The 2-year survival was observed in 
an encouraging 48%, and the regimen was deemed tolerable with only 16% 
and 5% of patients experiencing grade 3 and 4 dysphagia, respectively. The 
strategy of utilizing a once-daily fractionation scheme to 70 Gy continues 
to be evaluated in combination with novel chemotherapy regimens (18-19).
A number of clinical trials have suggested the maximum tolerated dose for 
hyperfractionated thoracic radiation delivered concurrent with cisplatin and 
etoposide chemotherapy to be in the range of 40 to 50 Gy (20). Esophagitis 
is often the dose-limiting toxicity in twice-daily radiation schemes. No ran-
domized trials have been completed that compare the efficacy of high-dose, 
once-daily radiation (70 Gy) with 45 Gy of hyperfractionated thoracic radiation 
therapy (21). Because of the increased toxicity and patient inconvenience 
associated with hyperfractionated radiation, the routine use of this approach 
in standard practice is often limited to selected patients (22). Additional phase 
III trials are needed to address the issues of hyperfractionation and the effect 
of overall treatment time. In Canada, 40 Gy in 3 weeks is still widely used (23). 
we really do not know that longer treatments or higher doses are better for 
local control or survival, but we are now able to deliver doses up to 70 Gy in 
7 weeks (17) without a clear signal that higher doses are superior. At present, 
once-daily thoracic radiation doses in the range of 50 Gy to 60 Gy would 
reflect an accepted standard of care in daily practice (24).
Chemotherapy  remains  the  cornerstone  for  therapy  of  SCLC.  However, 
the  addition  of  thoracic  radiotherapy  to  standard  chemotherapy  has 
led to improvements in long-term survival in patients with LS – SCLC. 
Comparison of the 2-year survival rates showed a 5.4% improvement for 
patients who received radiation therapy. The 5% increase in absolute sur-
vival in patients receiving thoracic radiation represents a more than 50% 
relative  improvement  in  the  survival  rate  observed  with  chemotherapy 
alone. Local control rates were doubled from approximately 25% with 
chemotherapy alone to approximately 50% with the addition of thoracic 
radiation. Neither study reported the “best” chemotherapy and radiation 
regimen. However, the use of cisplatin (Platinol) and etoposide (VePesid) 
(PE) and concurrent thoracic radiation has been associated with the best 
survival results observed thus far.
The aim of our retrospective study was to evaluate two different radio-
therapy (RT) doses applied sequentially with chemotherapy (CT) on time to 
progression (TTP), progression free survival (PFS), and overall survival (OS) 
of the patients with limited disease (LD) of small-cell lung cancer (SCLC). 
MATERIAL AND METHODS
Eighty-one newly diagnosed patients with histologically confirmed small-
cell lung cancer received their initial treatment (combined chemo- and 
radiotherapy) from 1998 through 2003 at the of Oncology Clinic, Clinical 
Centre  of  Montenegro.  The  patients  and  tumors  characteristics  are 
described in Table 1.
The patients were evaluated for disease stage before the initiation of che-
motherapy and chest radiotherapy. Their anamneses were taken and they 
all had physical examination, complete and differential blood cell count, 
serum chemistry examination, and urine analysis. Imaging examinations 
included chest roentgenogram, computed tomography of the chest, mag-
netic resonance imaging or computed tomography of the head, radionuclide 
bone scan with radiographs of areas of increased radionuclide uptake, and 
computed tomography or radionuclide scan of the liver. The patients also 
underwent  fiber-optic  bronchoscopy  and  pulmonary  function  tests  with 
arterial blood gases. Limited-stage disease was defined as tumor confined 
to one hemithorax and hilar, mediastinal, and supraclavicular nodes and 
encompassed within a tolerable radiotherapy portal after completion of the 
staging evaluation. Patients with extrapulmonary small-cell cancer whose 
cancer was confined to an anatomic area that could be encompassed within 
a tolerable radiation portal were also treated with this regimen. The diagno-
sis of SCLC was based on histologic examination of a bronchial biopsy and/
or lymph node metastasis.
The eligibility criteria for patient entry included no active second malignancy and 
an ECOG performance status of 0 to 2. Patients also needed adequate hemato-
logic function, defined as a wBC count greater than 4,000/pL and platelet count 
greater than 100,000/pL, adequate renal function with a serum creatinine level 
less than 2.0 mg/dL, and adequate cardiac function, defined as no symptomatic 
heart disease, no less than fully compensated congestive heart failure, and no 
significant arrhythmia or myocardial infarction within the past 3 months. 
All patients were given chemotherapy with the same drugs (cisplatin and eto-
poside) followed by chest radiotherapy after the forth cycle of chemotherapy. 
The initial therapy consisted of etoposide 100 mg/m
2 administered on days 
1, 2, and 3, and cisplatin 80 mg/m
2 on day 1; 3 weeks for 4 cycles followed 
by radiotherapy. Chest irradiation to the primary tumor and involved lymph 
nodes of mediastinum started 4 weeks after the last cycle of chemotherapy. 
The radiotherapy doses were prescribed at midplane for anterior-posterior, 
posterior-anterior (AP-PA) fields and to specific isodose curves to cover the 
tumor volume for non AP-PA techniques (3 and 4 fields). All patients’ irradi-
ated tumor volumes were simulated. Tumor volumes were defined by chest 
radiograph and computed tomography of the chest before initiation of che-
motherapy treatment, and the gross tumor volume (GTV) was encompassed 
by a minimum margin of 1.5 cm throughout the treatment course. Ipsilateral 
hilum and bilateral mediastinum from thoracic inlet to subcarinal region (5 cm 
bellow carina) were included. Contralateral hilum or supraclavicular was not 
included unless involved. Irradiation was administered in one-daily fraction 
with isocentre technique to a total dose of 44 Gy in 22 fractions (group I) and 
54 to 64 Gy in 27 to 32 fractions (group II). All patients were treated on the 
linear accelerator, Clinac 600C, Varian, x rays with energy of 6 MV. 
Statistical methods
The lengths of time until treatment failure – time to progression (TTP) were 
measured from the date of the end of radiotherapy course. Progression free 
survival (PFS) was the length of time after radiotherapy treatment in which our 
patients were living with a disease that did not get worse. Overall survival (OS) 
was calculated as the length of time until death, irrespective of cause. The values 
were compared by chi square test and Fisher test. we used the life table method 
to estimate the probability of treatment failure for the endpoints of PFS and OS.
 RESULTS
From 1998 to 2003, 81 patients (65 men and 16 women) were treated 
in this study. Male: female ratio was 4:1. At the time of study entry, their 
median age was 57 years (range, 36 to 77). The majority of the patients 10
Articles
www.onk.ns.ac.rs/Archive  Vol 18, No. 1-2, July 2010
were 50 to 59 years old. All patients had limited-stage of disease. The 
patients had ECOG status 0 and 1, mostly (88%) (Table 1). All patients com-
pleted four cycles of etoposide/cisplatin chemotherapy and the full planned 
course of chest radiotherapy. 
The median follow-up time was 23 months (range, 12-72 months) for both 
groups of patients. Relapse rate and sites of distant metastases are showed 
in Table 2 and Figure 1.
The most often combination of metastases’ sites was brain and lymph 
nodes of the neck in 6 patients and brain, liver, and bone metastases in 7 
patients. The rest of patients had other combination of distant metastases 
(bone and brain, liver and bone, liver and lymph nodes). However, there 
were  no  statistically  significant  difference  in  relapse  rate  between  two 
groups of patients (p>0.05, Fisher test). Brain metastases were observed 
in 37% of patients in both groups of patients, alone or combined with 
Total number of patients (81) Number of patients Percent of all patients (%)
Gender:
Male 
Female 
65
16
80
20
Age range (years):
30-39
40-49
50-59
60-69
70- 79
Median (range):
57 years (36 – 77 years) 
2
18
32
18
11
2
22
40
22
14
Performance status (ECOG)
*:
0
1
2
28
43
10
35
53
12
Histopathological status:
SCLC 81 100
Stage of disease:
Limited 81 100
Table 1. Patients and tumor characteristics 
*ECOG
 - Eastern Cooperative Oncology Group
 
Group I (No/%) Group II (No/%)
No relapse 1/2 4/10
Extrathoracic relapse 24/59 28/70
Intrathoracic relapse 1/2 4/10
Extrathoracix and intrathoracic relapses 15/37 4/10
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Liver  Bone Neck Brain Combination
Table 2. Relaps rate
Figure 1. Sites of distant metastases 
  Group 1,    Group 211
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other sites of metastases. whole brain irradiation was performed for these 
patients with total dose of 30 Gy in 10 fractions.
The most common cause of treatment-related morbidity was combined 
modality esophagitis in both groups of patients. Four of 41 patients (10%) 
and 7 of 40 patients (17.5%) had esophagitis (grade 3 toxicity) respectively. 
In group II of patients, 3 of 40 patients (7.5%) had pneumonitis grade 2 that 
required administration of corticosteroids. There were no treatment- related 
deaths in any group of patients.
Of the original 81 patients, 6 patients (7%) from group II were alive and free 
of cancer at 2 years. The other 75 patients (93%) had relapsed and died.
The  median TTP  in  group  I  of  patients  was  13  months  (range,  11-29 
months) while median TTP in group II of patients was 20 months (range, 
9-60 months).
There was difference but not statistically significant in 1 year PFS (p=0.05, 
chi-square test) while there was statistically significant difference in 2 years 
PFS favoring higher doses of RT (p<0.05, chi-square test) (Table 3, Figure 2).
The  median  OS  was  18  months  (range  12-35  months)  in  group  I  of 
patients  with  two-year  survival  rate  of  5%  while  median  OS  was  28 
months (range, 15-72 months) in second group of patients with two-year 
survival rate of 53%. There were no statistically significant advantage in 
either of the two groups patients regarding one-year OS (p>0.05, chi-
square test). However, there were statistically significant difference in 
OS favoring higher RT doses for two-year OS (p<0.001, chi-square test) 
(Table 3, Figure 3).
DISCUSSION
Limited-stage small-cell lung cancer remains a therapeutic challenge to 
medical and radiation oncologists. SCLC is characterized by a more rapid 
doubling time and higher growth fraction, making either micrometastatic 
or macrometastatic disease a hallmark of the disease. This aspect of the 
natural history of SCLC, combined with the initial sensitivity of SCLC to both 
chemotherapy  and  radiation  therapy,  have  clearly  influenced  the  thera-
peutic approach to this disease. The percentage of patients left unstaged 
has declined (17.9% in 1973 vs. 3.8% in 2002), and the use of combined 
chemoradiotherapy as primary treatment has increased (34.8% in 1985 vs. 
51.9% in 2000) (2). 
The  treatment  of  LS-SCLC  has  evolved  significantly  over  the  last  two 
decades with combined-modality therapy now the standard of care (25). 
In LS-SCLC, combination chemotherapy alone results in poor local control 
rates, with intra thoracic failures occurring in 75% to 90% of patients (26). 
The addition of thoracic radiotherapy (TRT) significantly reduced the risk of 
intra thoracic failures from 60% to 30% but did not consistently result in a 
survival advantage in individual trials. Pignon et al. evaluated 13 random-
ized trials including 2,410 patients with LS-SCLC. These studies have inves-
tigated the role of thoracic radiotherapy in LS-SCLC. The relative risk (RR) of 
death in the chemo radiotherapy group compared with the chemotherapy 
alone group was 0.86 (95% CI, 0.78 to 0.94; P = .001), corresponding to 
a 14% reduction in mortality and an absolute benefit in overall survival of 
5.4% +/- 1.4% at 3 years. There was a trend towards a greater reduction 
in mortality among younger patients. The 2-year local failure rate of 23% 
Table 3. Differences between groups in one-year and two-year PFS and OS
Year 1 of the treatment end (p) Year 2 of the treatment end (p) Two-year PFS and OS (p)
Group I
 
42% 2%
PFS
Group II 65%
(p = 0.05)
20%
(p < 0.05)
p < 0.05
Group I
 
98% 5%
OS
 Group II 100%
(p > 0.05)
53%
(p < 0.05)
p < 0.001
0
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months
% patients
< 45 Gy of RT doses > 45 Gy of RT doses
p=0.05 
p<0.05 
Figure 2. Progression free survival for both groups of patients12
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for irradiated patients vs. 48% for nonirradiated patients remains significant 
as well (P = .0001). No clear benefit was noted in an indirect comparison 
of early versus late TRT or sequential versus nonsequential strategies (6-7). 
Having established TRT as an integral component of the treatment platform 
for LS-SCLC, many issues remain unresolved regarding the optimal chemo 
radiotherapy approach. One issue is the dose of TRT. Traditionally, mod-
est doses of TRT (45 to 50 Gy), in daily 1.8- to 2-Gy fractions, were used 
because of the radiotherapy sensitivity of SCLC (27). Intensifying the radio-
therapy dose by accelerating its delivery was one of the initial strategies 
explored in prospective LS-SCLC trials. Turrisi et al randomly assigned 471 
LS-SCLC patients to either 45 Gy in 5 weeks (1.8Gy every day for 25 frac-
tions) or 45 Gy in 3 weeks (1.5 Gy bid for 30 fractions) beginning with the 
first of four cycles of EP. The 5-year survival rate was 26% with accelerated 
TRT compared with 16% for conventional TRT. The major toxicity seen with 
accelerated TRT was a doubling of the grade 3 or 4 esophagitis rate (16% 
for convention TRT vs. 32% for accelerated TRT); severe pulmonary toxicity 
was similar on both arms of the trial (approximately 6% grade 3). There was 
a significant difference in favor of the accelerated TRT arm in overall local 
tumor control (e.g., local as well as local plus distant recurrence) (21). This 
data strongly suggested that attempts designed to improve local control 
could favorably affect the long-term outcome of patients with LS-SCLC. 
Despite the significant improvement in long-term survival, the adopting of 
45 Gy bid as a new standard failed to occur perhaps because of the incon-
venience of twice-daily treatment sessions and the increased rate of severe 
esophageal toxicity seen with this regimen (25, 28,29).
The purpose of our study was the administration of a higher total dose of 
once-daily TRT to increase the efficacy of treatment. There were no statisti-
cally significant advantages between two groups of patients for 1-year PFS 
(p=0.05, chi square) and OS (p>0.05, chi square). However, there were sta-
tistically significant differences in PFS and OS favoring higher RT doses for 
2-year PFS (p<0.05, chi square) and OS (p<0.001). Our results were worse 
than actually trials (in the references 4, 9, 11, 12, 16-19, 22-23, 28) (median 
TTP = 20 months; two-year PFS was 20%; median OS = 28 months with 
two-year OS 53%). we suppose that the delay of the initiation of TRT after 
the fourth cycle of chemotherapy was the reason for these results. The 
toxicity of our treatment was similar to the toxicity in other studies regard-
ing once-daily TRT with total dose escalation (esophagitis grade 3 in 17.5% 
patients and pneumonitis grade 2 in 7.5% patients).
The optimal timing of TRT relative to chemotherapy remains controversial. 
At least five meta-analyses addressing the timing of TRT have recently been 
published (10, 12, 24). Fried et al., showed an advantage to early (adminis-
tered within 9 weeks of starting chemotherapy) versus late TRT in terms of 
survival. This was particularly evident when cisplatin-based chemotherapy 
regimens and more intensified TRT were used (10). De Ruysscher et al. (11) 
also reported similar findings with regard to survival when TRT was started 
within 30 days of chemotherapy initiation. The survival advantage was more 
pronounced if the TRT was completed in less than 30 days (11, 30-34).
CONCLUSION
Many  questions  remain  about  the  optimal  way  to  deliver  chemoradio-
therapy. we found that higher RT doses applied sequentially with CT had 
influence on long-term TTP, PFS, and OS of our patients (2 years).
The future efforts in this disease should focus on optimizing TRT concerning 
the optimal doses, fractionation, timing, appropriate target volume, and the 
use of concurrent vs. sequential protocols. For prophylactic cranial irradia-
tion (PCI), there is some evidence supporting a linear dose-effect relation-
ship, but convincing data on the toxicity/efficacy ratios are still missing. 
LS-SCLC has been a model cancer in terms of the potential benefit of 
combined chemo- radiotherapy strategies in improving patient outcomes. 
All patients in excellent overall health should be treated aggressively with 
both radiation and chemotherapy. In addition, the further randomized trials 
should focus on unraveling the biology of LS-SCLC, which would hopefully 
lead to more effective systemic therapies.
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